RIGL Rigel Pharmaceuticals PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: RIGL
- PE Ratio
The P/E ratio for Rigel Pharmaceuticals stock stands at 9.0 as of May 8, 2025. The calculation is based on the latest EPS of $2.1 and the stock price of $18.9 per share.
RIGL PE ratio history
Rigel Pharmaceuticals PE ratio by year
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | 16.99 | N/A | $16.82 | $0.99 |
| 2023 | N/A | N/A | $14.5 | -$1.44 |
| 2022 | N/A | N/A | $15 | -$3.44 |
| 2021 | N/A | N/A | $26.5 | -$1.1 |
| 2020 | N/A | N/A | $35 | -$1.8 |
| 2019 | N/A | N/A | $21.4 | -$4 |
| 2018 | N/A | N/A | $23 | -$4.4 |
| 2017 | N/A | N/A | $38.8 | -$6.2 |
| 2016 | N/A | N/A | $23.8 | -$7.3 |
| 2015 | N/A | N/A | $30.3 | -$5.8 |
| 2014 | N/A | N/A | $22.7 | -$10.4 |
| 2013 | N/A | N/A | $28.5 | -$10.2 |
| 2012 | N/A | N/A | $65 | -$13.2 |
| 2011 | N/A | N/A | $78.9 | -$13.6 |
| 2010 | 10.32 | N/A | $75.3 | $7.3 |
Rigel Pharmaceuticals PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2025 | 8.57 | -49.56% | $17.99 | $2.1 |
| Dec 2024 | 16.99 | -75.85% | $16.82 | $0.99 |
| Sep 2024 | 70.35 | N/A | $16.18 | $0.23 |
| Jun 2024 | N/A | N/A | $8.22 | -$0.81 |
| Mar 2024 | N/A | N/A | $14.8 | -$1.13 |
| Dec 2023 | N/A | N/A | $14.5 | -$1.44 |
| Sep 2023 | N/A | N/A | $10.8 | -$1.45 |
| Jun 2023 | N/A | N/A | $12.9 | -$2.22 |
| Mar 2023 | N/A | N/A | $13.2 | -$2.64 |
| Dec 2022 | N/A | N/A | $15 | -$3.44 |
| Sep 2022 | N/A | N/A | $11.8 | -$4.9 |
| Jun 2022 | N/A | N/A | $11.3 | -$5 |
| Mar 2022 | N/A | N/A | $29.9 | -$5 |
| Dec 2021 | N/A | N/A | $26.5 | -$1.1 |
| Sep 2021 | N/A | N/A | $36.3 | -$0.9 |
RIGL average PE ratio chart
RIGL PE vs peers
When compared to its peer stocks AZN and AMGN, RIGL's PE ratio is lower.
| Stock name | PE ratio | Market cap |
|---|---|---|
| RIGL Rigel Pharmaceuticals Inc | 9 | $337.79M |
| AMGN Amgen Inc | 24.62 | $146.28B |
| AZN Astrazeneca plc | 26.81 | $208.63B |
| SGMO Sangamo Therapeutics Inc | N/A | $161.75M |
| XOMA XOMA Corp | N/A | $292.76M |
Frequently asked questions
What is Rigel Pharmaceuticals's PE ratio?
RIGL stock has a price to earnings ratio of 9 as of May 8, 2025.
Why is Rigel Pharmaceuticals's PE ratio so low?
RIGL's stock price is trading at a lower multiple of earnings, which is why its PE ratio of 9 is considered low.
How is RIGL's PE ratio calculated (Rigel Pharmaceuticals PE ratio formula)?
To determine the P/E ratio, divide the latest stock price by the TTM earnings per share (EPS). As of today (May 8, 2025), Rigel Pharmaceuticals's share price is $18.9. The company's earnings per share for the trailing twelve months (TTM) ending Mar 2025 is $2.1. Therefore, Rigel Pharmaceuticals's price to earnings ratio for today is 9. PE RATIO(9) = STOCK PRICE($18.9) / TTM EPS($2.1)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.